Literature DB >> 20187063

Neoadjuvant therapy for pancreatic cancer: a current review.

Daniel E Abbott1, Marshall S Baker, Mark S Talamonti.   

Abstract

The optimal therapy for pancreatic cancer continues to evolve. Neoadjuvant chemoradiation is a key component of current treatment regimens, and evaluation of previous treatment options will help guide future trials. Here the authors present a review of the current literature with discussion of future directions.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20187063     DOI： 10.1002/jso.21469

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN： 0022-4790            Impact factor:   3.454


  9 in total

1.  Differentiation of noncalculous periampullary obstruction: comparison of CT with negative-contrast CT cholangiopancreatography versus MRI with MR cholangiopancreatography.

Authors:  Bin Li; Lei Zhang; Zhui-Yang Zhang; Jian-Ming Ni; Feng-qi Lu; Wen-Juan Wu; Chun-juan Jiang
Journal:  Eur Radiol       Date:  2014-09-24       Impact factor: 5.315

Review 2.  The Multidisciplinary Approach to Localized Pancreatic Adenocarcinoma.

Authors:  Hiral D Parekh; Jason Starr; Thomas J George
Journal:  Curr Treat Options Oncol       Date:  2017-11-16

Review 3.  Neoadjuvant therapy for pancreas cancer: past lessons and future therapies.

Authors:  Jeffrey M Sutton; Daniel E Abbott
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

4.  Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.

Authors:  Evan S Glazer; Cihui Zhu; Katheryn L Massey; C Shea Thompson; Warna D Kaluarachchi; Amir N Hamir; Steven A Curley
Journal:  Clin Cancer Res       Date:  2010-12-01       Impact factor: 12.531

5.  Adjuvant chemotherapy versus observation following neoadjuvant therapy and surgery for resectable stage I-II pancreatic cancer.

Authors:  Sung Jun Ma; Lucas M Serra; Austin J Bartl; Hye Ri Han; Fatemeh Fekrmandi; Austin J Iovoli; Gregory M Hermann; Han Yu; Anurag K Singh
Journal:  J Radiother Pract       Date:  2021-04-14

6.  Molecular characteristics of pancreatic ductal adenocarcinoma.

Authors:  Niki A Ottenhof; Roeland F de Wilde; Anirban Maitra; Ralph H Hruban; G Johan A Offerhaus
Journal:  Patholog Res Int       Date:  2011-03-27

7.  Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.

Authors:  Lucie Oberic; Frédéric Viret; Charlotte Baey; Marc Ychou; Jaafar Bennouna; Antoine Adenis; Didier Peiffert; Françoise Mornex; Jean-Pierre Pignon; Patrice Celier; Jocelyne Berille; Michel Ducreux
Journal:  Radiat Oncol       Date:  2011-09-26       Impact factor: 3.481

8.  Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749).

Authors:  Michael Tachezy; Florian Gebauer; Cordula Petersen; Dirk Arnold; Martin Trepel; Karl Wegscheider; Phillipe Schafhausen; Maximilian Bockhorn; Jakob Robert Izbicki; Emre Yekebas
Journal:  BMC Cancer       Date:  2014-06-07       Impact factor: 4.430

Review 9.  Multidisciplinary neoadjuvant management for potentially curable pancreatic cancer.

Authors:  Neelam V Desai; Sarunas Sliesoraitis; Steven J Hughes; Jose G Trevino; Robert A Zlotecki; Alison M Ivey; Thomas J George
Journal:  Cancer Med       Date:  2015-03-13       Impact factor: 4.452
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.